Wake Forest Health Sciences Dermatology
Winston-Salem, North Carolina, 27104, United States
NCT Number: NCT01444989
Actinic keratoses (AKs) are some of the most common lesions seen by dermatologists. Flesh colored to erythematous, these lesions often present with scaling or crusting in sun damaged regions of the body. While they are physically visible and often palpable, these changes can also result in psychosocial changes in patients, including embarrassment about their skin or reduction in leisure activities to avoid further sun exposure. At the same time, AKs are known to progress in a significant number of cases to squamous cell carcinoma (SCC), a concern in terms of its metastatic potential.
The primary purpose of developing this questionnaire is to examine how well it can potentially identify patients with actinic keratoses. However, since AK is associated with significant detriment to quality of life for validity/reliability assessment, the investigators propose to give a compilation of four self-assessment questionnaires (not specific to AK but validated for skin health in general) to subjects with at least one actinic keratosis and age- and sex- matched participants without AKs, defined as the control population. These will include the SKINDEX-16, the DLQI and the Skin Health Calculator, as well as a questionnaire composed of items specific to predisposition to AKs to be able to better assess the discriminatory power of the questionnaire.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Winston-Salem, North Carolina, 27104, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The AKRQ is an experimental instrument composed of 10 questions that assess quality of life and risk factors
These are all previously validated questionnaires
Time frame: Baseline
We are developing an actinic keratosis risk assessment questionnaire and is designed to distinguish patients who have a higher likelihood of having a diagnosis of actinic keratosis. The outcome measure is the difference in scores between those with actinic keratosis and those without.
Time frame: Baseline
The DLQI is a validated instrument. We will report how well our new instrument correlates with the DLQI.
Time frame: Baseline
The Skindex-16 is a validated instrument. We will report how well our new instrument correlates with the Skindex-16.
Time frame: Baseline
The Skin health calculator is a validated instrument. We will report how well our new instrument correlates with the Skin Health Calculator
Wake Forest University
Other
Acronym: AKRQ
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00375739
Actinic Keratosis, Hyperpigmentation
Huntsville, Alabama, United States
View Trial DetailsNCT00107965
Actinic Keratosis, Hyperpigmentation
Sydney, New South Wales, Australia
View Trial DetailsNCT06888362
Actinic Keratosis, Keratosis
Uppsala, Sweden
View Trial DetailsNCT06027619
Actinic Keratosis, Keratosis
Cleveland, Ohio, United States
View Trial Details